These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32650667)

  • 21. Lessons learned in methods and analyses for pragmatic studies.
    Eckardt P; Erlanger AE
    Nurs Outlook; 2018 Sep; 66(5):446-454. PubMed ID: 30131168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understudied populations with hepatitis C.
    Strader DB
    Hepatology; 2002 Nov; 36(5 Suppl 1):S226-36. PubMed ID: 12407598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Summaries for patients. Who gets antiviral treatment for hepatitis C?
    Ann Intern Med; 2002 Feb; 136(4):I48. PubMed ID: 11848740
    [No Abstract]   [Full Text] [Related]  

  • 24. Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial.
    Garcia CJ; Haynes K; Pokorney SD; Lin ND; McMahill-Walraven C; Nair V; Parlett L; Martin D; Al-Khalidi HR; McCall D; Granger CB; Platt R; Cocoros NM
    Clin Trials; 2020 Aug; 17(4):360-367. PubMed ID: 32589056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
    Edlin BR; Seal KH; Lorvick J; Kral AH; Ciccarone DH; Moore LD; Lo B
    N Engl J Med; 2001 Jul; 345(3):211-5. PubMed ID: 11463019
    [No Abstract]   [Full Text] [Related]  

  • 26. Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers.
    Sonnad SS; Mullins CD; Whicher D; Goldsack JC; Mohr PE; Tunis SR
    Contemp Clin Trials; 2013 Nov; 36(2):356-61. PubMed ID: 23999501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
    D'heygere F; George C; Habersetzer F; Tripathi D; Q Pan C; Giron JA; Schmitz M; Tatsch F
    Ann Hepatol; 2014; 13(2):303-4. PubMed ID: 24558225
    [No Abstract]   [Full Text] [Related]  

  • 28. Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people.
    Giannini EG; Romagnoli P; Testa R
    Am J Gastroenterol; 2006 Feb; 101(2):406-7. PubMed ID: 16454854
    [No Abstract]   [Full Text] [Related]  

  • 29. Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital.
    Tran AN; Sachdev R; Fricker ZP; Leber M; Zahorian T; Shah B; Nunes DP; Long MT
    Dig Dis Sci; 2018 Dec; 63(12):3241-3249. PubMed ID: 30078116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C Treatment Uptake by New Prescribers After the Introduction of Direct Acting Antivirals.
    Kapadia SN; Johnson P; Schackman BR; Bao Y
    J Gen Intern Med; 2020 Mar; 35(3):975-977. PubMed ID: 31325131
    [No Abstract]   [Full Text] [Related]  

  • 31. The Opportunities and Challenges of Pragmatic Randomized Trials Using a Specialized Software: CloudTrials Project.
    Fosser SM; Kamozin A; McDonald EG; Tamblyn R; Lee TC
    Stud Health Technol Inform; 2019 Aug; 264():1544-1545. PubMed ID: 31438223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The treatment of hepatitis C].
    Orlent H; Vrolijk JM; de Man RA; Schalm SW
    Ned Tijdschr Geneeskd; 2003 Jun; 147(25):1208-13. PubMed ID: 12848055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progression of treatment of hepatitis C--peginterferon].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2001; 55 Suppl 3():169-73. PubMed ID: 11984947
    [No Abstract]   [Full Text] [Related]  

  • 34. Explanatory trials versus pragmatic trials.
    Sedgwick P
    BMJ; 2014 Nov; 349():g6694. PubMed ID: 25395503
    [No Abstract]   [Full Text] [Related]  

  • 35. Pragmatism in practice: lessons learned during screening and enrollment for a randomised controlled trial in rural northern Ethiopia.
    Molla M; Negussie H; Ngari M; Kivaya E; Njuguna P; Enqueselassie F; Berkley JA; Davey G
    BMC Med Res Methodol; 2018 Mar; 18(1):26. PubMed ID: 29514613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?
    Gray E; Norris S; Schmitz S; O'Leary A
    J Comp Eff Res; 2017 Jan; 6(1):65-82. PubMed ID: 27854129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of decision intent within descriptions of pragmatic trials.
    Nicholls SG; Zwarenstein M; Hey SP; Giraudeau B; Campbell MK; Taljaard M
    J Clin Epidemiol; 2020 Sep; 125():30-37. PubMed ID: 32422248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. France removes hepatitis C treatment prescriber restrictions-But what is the impact of the delay for key populations?
    Marcellin F; Roux P; Lazarus JV; Rolland B; Carrieri P
    Liver Int; 2019 Dec; 39(12):2418-2419. PubMed ID: 31436366
    [No Abstract]   [Full Text] [Related]  

  • 39. The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials.
    Welch MJ; Lally R; Miller JE; Pittman S; Brodsky L; Caplan AL; Uhlenbrauck G; Louzao DM; Fischer JH; Wilfond B
    Clin Trials; 2015 Oct; 12(5):503-10. PubMed ID: 26374681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Need-adapted HCV-treatment setting for injection drug users.
    Reimer J; Haasen C
    Lancet; 2009 Jun; 373(9681):2090-1. PubMed ID: 19376573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.